KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Tax Provisions (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Tax Provisions for 17 consecutive years, with $218000.0 as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions rose 87.93% year-over-year to $218000.0; the TTM value through Mar 2026 reached $1.9 million, up 130.81%, while the annual FY2025 figure was $1.8 million, 128.94% up from the prior year.
  • Tax Provisions hit $218000.0 in Q1 2026 for Ionis Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $11.4 million in Q1 2023 and bottomed at -$3.6 million in Q3 2024.
  • Average Tax Provisions over 5 years is $2.3 million, with a median of $300000.0 recorded in 2022.
  • Year-over-year, Tax Provisions skyrocketed 2231.52% in 2022 and then crashed 154.85% in 2024.
  • Ionis Pharmaceuticals' Tax Provisions stood at $8.1 million in 2022, then decreased by 20.17% to $6.5 million in 2023, then crashed by 141.41% to -$2.7 million in 2024, then soared by 154.94% to $1.5 million in 2025, then tumbled by 85.25% to $218000.0 in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $218000.0, $1.5 million, and $213000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.